Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News PAVmed Inc PAVM

Alternate Symbol(s):  PAVMZ

Healthcare Medical Devices
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device... see more

Recent & Breaking News (NDAQ:PAVM)

PAVmed Launches Digital Health Company Veris Health Inc.

GlobeNewswire June 2, 2021

PAVmed Subsidiary Lucid Diagnostics Receives CE Mark Certification for its EsoCheck® Esophageal Cell Collection Device

GlobeNewswire May 26, 2021

PAVmed Receives European CE Mark Certification for its CarpX® Minimally Invasive Carpal Tunnel Device

GlobeNewswire May 25, 2021

Data Presented at Digestive Disease Week 2021 Support Clinical Utility of PAVmed Subsidiary Lucid Diagnostics' EsoCheck and EsoGuard Technologies

GlobeNewswire May 24, 2021

PAVmed Provides Business Update and First Quarter 2021 Financial Results

GlobeNewswire May 17, 2021

PAVmed Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021

GlobeNewswire May 13, 2021

PAVmed Subsidiary Lucid Diagnostics Expands Commercial Leadership Team

GlobeNewswire May 6, 2021

PAVmed to Hold Business Update Conference Call on May 17, 2021

GlobeNewswire May 3, 2021

Dr. Jacque Sokolov Joins PAVmed Subsidiary Lucid Diagnostics' Board of Directors

GlobeNewswire April 29, 2021

Global Industry Executive Debbie White Joins PAVmed Board of Directors

GlobeNewswire April 27, 2021

PAVmed to Present at the 20th Annual Needham Healthcare Conference

GlobeNewswire April 8, 2021

PAVmed to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference

GlobeNewswire March 10, 2021

PAVmed Retires Convertible Debt

GlobeNewswire March 3, 2021

PAVmed Chairman and Chief Executive Officer Lishan Aklog, M.D., Elected to AdvaMed Board of Directors

GlobeNewswire March 1, 2021

PAVmed Announces Closing of its Public Offering of Common Stock

GlobeNewswire February 25, 2021

PAVmed Announces Pricing of $45 Million Public Offering of Common Stock

GlobeNewswire February 23, 2021

PAVmed Announces Proposed Public Offering of Common Stock

GlobeNewswire February 22, 2021

PAVmed Provides Business Update and Preliminary Fourth Quarter 2020 Financial Results

GlobeNewswire February 22, 2021

PAVmed Reschedules Business Update Conference Call on February 22, 2021 to 8:30 AM EST

GlobeNewswire February 18, 2021

First U.S. Patient Undergoes Successful Minimally Invasive Carpal Tunnel Release Using PAVmed's CarpX® Device

GlobeNewswire February 16, 2021